Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.46 USD
Change Today +0.0016 / 0.35%
Volume 394.2K
IMUC On Other Exchanges
As of 8:04 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

immunocellular therapeutics (IMUC) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/2/14 - $1.45
52 Week Low
04/10/15 - $0.43
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

immunocellular therapeutics (IMUC) Related Bloomberg News

View More Bloomberg News

immunocellular therapeutics (IMUC) Related Businessweek News

No Related Businessweek News Found

immunocellular therapeutics (IMUC) Details

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that completed Phase II testing trials for the treatment of glioblastoma multiforme (GBM). The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM and other solid tumor cancers; and ICT-140 for ovarian cancer. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

5 Employees
Last Reported Date: 03/10/15

immunocellular therapeutics (IMUC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $533.1K
Founder, Chairman, Chief Scientific Officer a...
Total Annual Compensation: $161.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $207.1K
Senior Vice President of Strategic Resources
Total Annual Compensation: $400.3K
Compensation as of Fiscal Year 2014.

immunocellular therapeutics (IMUC) Key Developments

ImmunoCellular Therapeutics, Ltd. Proposes Amendments to Amended and Restated Certificate of Incorporation

ImmunoCellular Therapeutics, Ltd. announced that at its annual meeting of stockholders to be held on June 26, 2015, it will propose a series of alternate amendments to the company's amended and restated Certificate of Incorporation, as amended, to effect, at the discretion of the Board of Directors: a reverse stock split of the company's common stock, whereby each outstanding 2, 3, 4, 5 or 10 shares would be combined, converted and changed into one share of common stock; and for reverse splits in the range of 1-for-3 to 1-for-10, a reduction in the number of authorized shares of the company's common stock from 149,000,000 to 99,000,000, 74,500,000, 59,500,000, or 29,500,000, respectively.

Richard Chin Not to Stand for Re-Election as Director of Immunocellular Therapeutics, Ltd

ImmunoCellular Therapeutics, Ltd. announced that on April 14, 2015, Richard Chin notified the Nominating and Corporate Governance Committee of the company that he will not stand for re-election as a director at the company's 2015 Annual Meeting of Stockholders. Dr. Chin will remain a director until the Annual Meeting and has no disagreements with the company relating to it's operations, policies or practices.

ImmunoCellular Therapeutics, Ltd. Announces Agreement with PharmaCell B.V. to Provide Contract Manufacturing Services

ImmunoCellular Therapeutics, Ltd. announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM). This agreement with PharmaCell, focuses on the production of human cell therapy products, and is designed to enable ImmunoCellular to access phase 3 supplies of ICT-107, manufactured with ImmunoCellular's commercial-ready production process. ImmunoCellular intends to initiate a Phase 3 registrational program for ICT-107 in the US and in Europe in 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMUC:US $0.46 USD +0.0016

IMUC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMUC.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMUC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOCELLULAR THERAPEUTICS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at